|Other Names||Mitochondrial amidoxime reducing component 2, mARC2, 1---, Molybdenum cofactor sulfurase C-terminal domain-containing protein 2, MOSC domain-containing protein 2, Moco sulfurase C-terminal domain-containing protein 2, MARC2, MOSC2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13573b was selected from the C-term region of MOSC2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively.|
|Cellular Location||Mitochondrion outer membrane; Peripheral membrane protein. Peroxisome|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Catalytic component of the benzamidoxime prodrug-converting complex, a complex required to reduce N-hydroxylated structures, such as benzamidoxime prodrug. Benzamidoxime is an amidine prodrug produced by N-hydroxylation which is used to enhance bioavailability and increase intestinal absorption. It is then reduced into benzamidine, its active amidine, by the benzamidoxime prodrug-converting complex.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Aberg, K., et al. Biol. Psychiatry 67(3):279-282(2010)Havemeyer, A., et al. J. Biol. Chem. 281(46):34796-34802(2006)Anantharaman, V., et al. FEMS Microbiol. Lett. 207(1):55-61(2002)Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.